Global Marfan Syndrome Market - 2024-2031

Global Marfan Syndrome Market - 2024-2031


Global Marfan Syndrome Treatment Market reached US$ XX million in 2023 and is expected to reach US$ XX million by 2031, growing at a CAGR of XX% during the forecast period 2024-2031.

Marfan syndrome is an inherited disorder that affects connective tissue the fibres that support and anchor the organs and other structures in the body. Marfan syndrome most commonly affects the heart, eyes, blood vessels, and skeleton. Treatment varies depending on the area of the body affected and may include medications, other therapies, and surgery to manage the condition and its complications. Research and advances in treatments and surgeries allow people with Marfan syndrome to live long, productive lives.

Market Dynamics: Drivers & Restraints

Rise in research and development

The rise in research and development is one of the major driving factors that help the overall market to grow during the forecast period. Research and development are advancing the understanding and treatment of Marfan syndrome through novel imaging methods, therapeutic targets, and machine-learning models.

For instance, in May 2023, a study suggested that fibronectin can potentially treat aortic aneurysms in individuals with Marfan Syndrome (MFS). The research indicates that integrin α5β1 in MFS is responsible for amplifying inflammatory responses, suggesting a new treatment approach for aortic aneurysms.

Side effects associated with the syndrome

Marfan syndrome affects different areas of the body, other problems and complications can develop, including, enlargement (aneurysm) of the main artery in the body (aorta), which happens when the wall of the aorta weakens and bulges. It is a life-threatening emergency if the wall of the aorta tears or ruptures. Cataracts are cloudy areas in the lens of the eye. Dural ectasia happens when the tissue that surrounds the spinal cord weakens and stretches.

Segment Analysis

The global Marfan syndrome treatment market is segmented based on treatment type, route of administration, end-user, and region.

The aortic dilation from the treatment type segment accounted for approximately 37.3% of the Marfan syndrome treatment market share

The aortic dilation from the treatment type segment accounted for approximately 37.3%. Marfan syndrome is a relatively common heritable disorder of connective tissue that affects numerous organ systems, but the most severe complication is aortic aneurysm and dissection. A variety of medical and surgical approaches are available for managing the cardiovascular complications.

For instance, in August 2022, according to the Marfan Foundation, a meta-analysis of seven global clinical trials involving 1442 participants with Marfan syndrome found that angiotensin receptor blockers (ARBs) significantly reduce the rate of aortic root enlargement in patients. The study found that ARBs, such as losartan and irbesartan, were effective even among those already taking beta-blockers. The rate-reducing effect was particularly significant among patients with a disease-causing FBN1 gene mutation, providing biological support for the effect.

Geographical Analysis

North America is estimated to hold about 38.4% of the total market share throughout the forecast period

North America is estimated to hold about 38.4% of the total market share throughout the forecast period owing to factors like the rise in the prevalence of Marfan syndrome in the United States, advancement in treatment options, FDA approvals, novel product launches, and other factors help the region to grow during the forecast period.

For instance, in Children's Wisconsin, an estimated 50,000 people in the United States have Marfan syndrome (or three out of every 5,000 people). Marfan syndrome occurs in equal numbers in males and females and also appears equally in all races and ethnic groups. It occurs in one in 20,000 live births.

Market Segmentation

By Treatment Type
• Aortic Dilation
• Beta Blocker
• Calcium Channel Blocker
• ACE Blocker
• Aortic root replacement
• Valve sparing root replacement
• Complex aortic surgery for dissections and aneurysms
• Others

By Route of Administration
• Oral
• Parenteral
• Others

By End-User
• Hospitals
• Clinics
• Others

By Region
• North America
U.S.
Canada
Mexico
• Europe
Germany
UK
France
Italy
Spain
Rest of Europe
• South America
Brazil
Argentina
Rest of South America
• Asia-Pacific
China
India
Japan
South Korea
Rest of Asia-Pacific
• Middle East and Africa

Competitive Landscape

The major global players in the market include Mesa Science Associates Inc., Merck & Co. Inc., Aurobindo Pharma USA, Teva Pharmaceuticals, Lupin Pharmaceuticals, Inc., AdvaCare Pharma among others.

Key Developments

 In November 2023, a Pune team of eye surgeons at a city hospital successfully restored normal vision in a 35-year-old woman living with Marfan syndrome, a genetic disorder affecting connective tissue the fibers that support and anchor organs and other structures in the human body.

Why Purchase the Report?
• To visualize the global Marfan syndrome treatment market segmentation based on treatment type, route of administration, end-user, and region as well as understand key commercial assets and players.
• Identify commercial opportunities by analyzing trends and co-development.
• Excel data sheet with numerous data points of the Marfan syndrome treatment market level with all segments.
• PDF report consists of a comprehensive analysis after exhaustive qualitative interviews and an in-depth study.
• Product mapping available as Excel consisting of key products of all the major players.

The global Marfan syndrome treatment market report would provide approximately 64 tables, 61 figures, and 186 pages.

Target Audience 2023
• Manufacturers/ Buyers
• Industry Investors/Investment Bankers
• Research Professionals
• Emerging Companies


1. Methodology and Scope
1.1. Research Methodology
1.2. Research Objective and Scope of the Report
2. Definition and Overview
3. Executive Summary
3.1. Snippet by Treatment Type
3.2. Snippet by Route of Administration
3.3. Snippet by End User
3.4. Snippet by Region
4. Dynamics
4.1. Impacting Factors
4.1.1. Drivers
4.1.1.1. Rise in research and development
4.1.1.2. Rise in the prevalence of chronic diseases
4.1.2. Restraints
4.1.2.1. Side effects associated with the syndrome
4.1.2.2. XX
4.1.3. Opportunity
4.1.4. Impact Analysis
5. Industry Analysis
5.1. Porter's Five Force Analysis
5.2. Supply Chain Analysis
5.3. Pricing Analysis
5.4. Regulatory Analysis
5.5. Patent Analysis
5.6. PESTLE Analysis
5.7. SWOT Analysis
5.8. DMI Opinion
6. By Treatment Type
6.1. Introduction
6.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment Type
6.1.2. Market Attractiveness Index, By Treatment Type
6.2. Aortic Dilation*
6.2.1. Introduction
6.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
6.3. Beta Blocker
6.4. Calcium Channel Blocker
6.5. ACE Blocker
6.6. Aortic root replacement
6.7. Valve sparing root replacement
6.8. Complex aortic surgery for dissections and aneurysms
6.9. Others
7. By Route of Administration
7.1. Introduction
7.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
7.1.2. Market Attractiveness Index, By Route of Administration
7.2. Oral*
7.2.1. Introduction
7.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
7.3. Parenteral
7.4. Others
8. By End User
8.1. Introduction
8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
8.1.2. Market Attractiveness Index, By End User
8.2. Hospitals*
8.2.1. Introduction
8.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
8.3. Clinics
8.4. Others
9. By Region
9.1. Introduction
9.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
9.1.2. Market Attractiveness Index, By Region
9.2. North America
9.2.1. Introduction
9.2.2. Key Region-Specific Dynamics
9.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment Type
9.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
9.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
9.2.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
9.2.6.1. U.S.
9.2.6.2. Canada
9.2.6.3. Mexico
9.3. Europe
9.3.1. Introduction
9.3.2. Key Region-Specific Dynamics
9.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment Type
9.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
9.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
9.3.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
9.3.6.1. Germany
9.3.6.2. UK
9.3.6.3. France
9.3.6.4. Italy
9.3.6.5. Spain
9.3.6.6. Rest of Europe
9.4. South America
9.4.1. Introduction
9.4.2. Key Region-Specific Dynamics
9.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment Type
9.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
9.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
9.4.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
9.4.6.1. Brazil
9.4.6.2. Argentina
9.4.6.3. Rest of South America
9.5. Asia-Pacific
9.5.1. Introduction
9.5.2. Key Region-Specific Dynamics
9.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment Type
9.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
9.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
9.5.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
9.5.6.1. China
9.5.6.2. India
9.5.6.3. Japan
9.5.6.4. South Korea
9.5.6.5. Rest of Asia-Pacific
9.6. Middle East and Africa
9.6.1. Introduction
9.6.2. Key Region-Specific Dynamics
9.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment Type
9.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
9.6.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
10. Competitive Landscape
10.1. Competitive Scenario
10.2. Market Positioning/Share Analysis
10.3. Mergers and Acquisitions Analysis
11. Company Profiles
11.1. Mesa Science Associates Inc *
11.1.1. Company Overview
11.1.2. Product Portfolio and Description
11.1.3. Financial Overview
11.1.4. Key Developments
11.2. Merck & Co. Inc
11.3. Aurobindo Pharma USA
11.4. Teva Pharmaceuticals
11.5. Lupin Pharmaceuticals, Inc
11.6. AdvaCare Pharma
LIST NOT EXHAUSTIVE
12. Appendix
12.1. About Us and Services
12.2. Contact Us

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook
Cookie Settings